Market research
NCYT.LSE Novacyt S.A
LSE GBP Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 33M
- P/E ratio
- Not available
- Analyst target
- 66
- Dividend yield
- Not available
- Beta
- 1.11
Profile
Company facts
- Exchange
- LSE
- Currency
- GBP
- Sector
- Healthcare
- Industry
- Medical Devices
- ISIN
- FR0010397232
- Market cap
- 33M
- P/E ratio
- Not available
- Analyst target
- 66
- Dividend yield
- Not available
- Beta
- 1.11
About
About Novacyt S.A
Novacyt S.A., together with its subsidiaries, develops, manufactures, and commercializes a range of molecular assays and instrumentation to deliver workflows and services for human health, animal health, and environmental sectors. It operates through Yourgene Health and Primer Design segments. The Yourgene Health segment delivers molecular diagnostic and screening solutions, across reproductive health and precision medicine. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the areas of infectious diseases. It operates in the United Kingdom, France, Europe, the United States, the Asia Pacific, the Middle East, and Africa. The company was incorporated in 2006 and is based in Le Vésinet, France.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the NCYT.LSE discussion.
5 years, 4 months ago
Novacyt S.A is currently in a long term downtrend where the price is trading 47.4% below its 200 day moving average.
From a valuation standpoint, the stock is 98.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 6.1.
Based on the above factors, Novacyt S.A gets an overall score of 1/5.